Immunomodulation by the combination of ipilimumab and nivolumab neoadjuvant to (salvage) surgery in advanced or recurrent head and neck carcinoma, IMCISION, an investigator-initiated phase-Ib/II trial (N16IMC, NCT03003637)

Authors :: Charlotte L. Zuur
John B. A. G. Haanen
Wouter V. Vogel
Stefan M. Willems
J.P. de Boer
Laura A. Smit
Bing Tan
Joris B. W. Elbers
Abrahim Al-Mamgani
Michiel W. M. van den Brekel
Anne van der Leun
Christian U. Blank
Jasper Nijkamp
Ton N. Schumacher
Bas Jasperse
Source :: Journal of Clinical Oncology. 36:e18020-e18020
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: e18020Background: To assess safety, toxicity and efficacy of neo-adjuvant nivolumab ± ipilimumab administration to (salvage) surgery for squamous cell carcinoma of the head and neck (HNSCC). Method...

Subjects :: 0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
business.industry
Ipilimumab
stomatognathic diseases
03 medical and health sciences
030104 developmental biology
Internal medicine
Toxicity
medicine
Salvage surgery
Basal cell
Nivolumab
business
Head and neck
Head and neck carcinoma
medicine.drug

Tools